Provided by Tiger Trade Technology Pte. Ltd.

Rezolute, Inc.

4.01
-0.0600-1.47%
Post-market: 3.99-0.0200-0.50%19:30 EDT
Volume:1.65M
Turnover:6.64M
Market Cap:386.13M
PE:-5.37
High:4.20
Open:4.13
Low:3.97
Close:4.07
52wk High:11.46
52wk Low:1.07
Shares:96.29M
Float Shares:72.51M
Volume Ratio:1.05
T/O Rate:2.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7467
EPS(LYR):-0.7467
ROE:-59.04%
ROA:-35.32%
PB:3.83
PE(LYR):-5.37

Loading ...

Rezolute, - Open-Label Extension Phase Ongoing with High Participation and Improved Glycemic Control

THOMSON REUTERS
·
Sep 09

Rezolute, - Enrollment Ongoing in Phase 3 Uplift Study for Tumor Hi; Results Expected Before End of 2026

THOMSON REUTERS
·
Sep 09

Rezolute, - FDA Still Reviewing Submission for Regulatory Path Forward for Ersodetug in Congenital Hi

THOMSON REUTERS
·
Sep 09

Rezolute Provides Update on FDA Review of Its Phase 3 Sunrize Study Results in Congenital Hyperinsulinism

THOMSON REUTERS
·
Sep 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Sep 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Sep 04

Rezolute Says Cash Position Totals $120 Million, Funds Operations into Mid-2028

Reuters
·
Aug 26

Rezolute Shares to Show Strength Towards Upcoming Ersodetug Catalysts, Wedbush Says

MT Newswires Live
·
Aug 25

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)

TIPRANKS
·
Jul 30

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
Jul 14

Vivani Stock Puts These Obesity And Diabetes Treatment Stocks On The Radar

Simply Wall St.
·
Jul 12

Rezolute Posts Corporate Deck on Phase 3 Ersodetug Program for Refractory Hypoglycemia in Hyperinsulinism

Reuters
·
Jun 27

Rezolute highlights Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism at ENDO meeting

Reuters
·
Jun 17

Rezolute Is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 15

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)

TIPRANKS
·
Jun 10

Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT)

TIPRANKS
·
Jun 05

Rezolute flags Phase 3 sunRIZE top-line results for ersodetug in congenital hyperinsulinism at ENDO 2026

Reuters
·
Jun 04

Rezolute Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Jun 03

Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating

MT Newswires Live
·
Jun 03

Rezolute Is Maintained at Buy by BTIG

Dow Jones
·
Jun 03